The review summarizes the established and emerging pharmacological therapies for pulmonary arterial hypertension, highlighting the progress made over the past two decades.
No takes yet. Share an insight, caveat, or question.
Established PAH pathway therapies remain foundational in practice; leaves open safer targeted agents after imatinib setbacks.
Seferian et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: